---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-338011"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2026-08-06T20:10:59+00:00"
generated_at: "2026-08-06T20:14:49.922389+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical Q2 revenue $21.7M (+18% YoY), raises FY2026 guidance to $86-89M, expects Q4 cash flow breakeven

## Summary
- Q2 net revenue $21.7M (record), up 18% YoY and 13% sequentially; gross margin 81.9% (+70 bps YoY).
- Net loss improved to $7.7M ($0.25 loss per share) from $9.9M ($0.38) in prior year; operating expenses down 6% YoY.
- Raised FY2026 revenue guidance to $86-89M (from $80-85M), representing 20-24% YoY growth; expects Q4 2026 cash flow breakeven.
- Cash, equivalents, and marketable securities $11.1M; net cash use improved to $3.2M from $9.9M in Q1.
- CMS proposed 2027 Medicare payment updates for RECELL, including national physician payment and increased facility rates.

## SEC filing metadata
- accession: 0001193125-26-338011
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2026-08-06T20:10:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000119312526338011/0001193125-26-338011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000119312526338011/rcel-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-338011
- JSON: https://secwatch.observer/filing/0001193125-26-338011.json
- Plain text: https://secwatch.observer/filing/0001193125-26-338011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.